EPO对缺血性卒中脑损伤的保护作用及机制研究进展  

The Neuroprotective Effect of EPO on the Brain Ischemic Injury and the Relevant Mechanism

作　　者：张斯佳 罗玉敏 Sijia ZHANG;Yumin LUO(Institute of Cerebovacular Disease Research,Xuanwu Hospital of Capital Medical University)

机构地区：[1]首都医科大学宣武医院脑血管病研究室,北京100053

出　　处：《生命科学仪器》2019年第6期50-59,共10页Life Science Instruments

基　　金：国家自然科学基金面上项目(81641054,81071058,81471340)。

摘　　要：缺血性脑卒中引起的脑损伤是导致死亡和残疾的主要原因之一。由于大脑对血液供应中断非常敏感,在严重缺血10-15分钟后会遭受不可逆转的损伤。虽然重组组织纤溶酶原激活剂(recombinant tissue-type plasminogen activator,r-tPA)被证明对缺血性脑卒中的治疗有效,但其治疗时间窗较短,对于许多发病时间超过治疗时间窗的患者来说,目前尚无被证实有效的药物。越来越多的证据表明,促红细胞生成素(EPO)是一种强大的神经保护剂,可以在缺血性卒中的临床治疗中作为辅助治疗方法。EPO可以通过多种途径增强大脑对缺血再灌注损伤的抵抗能力,改善了脑缺血后的神经功能,促进神经功能的恢复。本文综述了EPO对于缺血性脑卒中的神经保护机制,探讨了EPO作为神经保护药物的临床应用前景。Brain injury caused by ischemic stroke is one of the main causes of death and disability.As the brain is so sensitive to disruption of blood supply,irreversible damage can occur after 10-15 minutes of severe ischemia injury.Although recombinant tissue-type plasminogen activator(rt-tPA)prove effective for ischemia stroke,its treatment time window is short.For patients whose onset time exceeds time window,there is no proven effective treatment by now.Increasing evidence have shown that erythropoietin(EPO)is a powerful neuroprotective agent and can be used as an adjunctive therapy in the treatment of ischemia stroke.EPO can enhance the brain’s resistance to ischemia reperfusion injury through a variety of ways,improve the neurological function after cerebral ischemia,and promote the recovery of neurological function.In this paper we review the mechanism of EPO’s neuroprotective effect for ischemic stroke and discuss the prospect of EPO as a neuroprotective drug.

关 键 词：促红细胞生成素 缺血性脑卒中 促红细胞生成素衍生物 

分 类 号：R743[医药卫生—神经病学与精神病学]